Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2014 / Cilt: 28 - Sayı: 1

Poor Clinical Outcome In A Good Controlled Neonatal Citrullinemia Patient

İYİ KONTROLLÜ BİR NEONATAL SİTRÜLLİNEMİ OLGUSUNDA KÖTÜ KLİNİK BULGULAR

Pages
31–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we described a 10 day old infant with neonatal citrullinemia without significant hyperammonemia, who had rapidly progressive clinical deterioration and elevated values of creatine kinase

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The classic citrullinemia is an autosomal recessive, metabolic disease that is caused by deficiency of the argininosuccinate synthetase.
📊
Key Findings & Data:Dietary protein restriction, the use of sodium benzoate arginine and phenylbutyrate are the main treatment strategies to eliminate the nitrogen and ammonia from the blood.
💡
Conclusion & Impact:Here, we described a 10 day old infant with neonatal citrullinemia without significant hyperammonemia, who had rapidly progressive clinical deterioration and elevated values of creatine kinase
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The classic citrullinemia is an autosomal recessive, metabolic disease that is caused by deficiency of the argininosuccinate synthetase. The clinical presentation is usually nonspecific and ranging from neonatal metabolic decompensation to adult onset form related to hyperammonemia and citrullinemia. Dietary protein restriction, the use of sodium benzoate arginine and phenylbutyrate are the main treatment strategies to eliminate the nitrogen and ammonia from the blood. The mechanisms responsible for the encephalopathy and central nervous system injury are not fully understood. High serum ammonia concentrations and intracerebral accumulation of glutamine in astrocytes is considered to be the major causes of the encephalopathy. Here, we described a 10 day old infant with neonatal citrullinemia without significant hyperammonemia, who had rapidly progressive clinical deterioration and elevated values of creatine kinase

Özet

Klasik sitrüllinemi, arjininosüksinat sentetaz eksikliğinin neden olduğu, otozomal resesif geçişli bir metabolik hastalıktır. Başvurudaki klinik bulguları genellikle spesifik değildir ve neonatal metabolik dekompanzasyondan, erişkin başlangıçlı forma kadar değişkenlik gösterebilir. Kandaki nitrojen ve amonyağı elimine etmek amacıyla kullanılan sodyum benzoat, arjinin, fenilbutirat ve protein kısıtlaması esas tedavi yöntemleridir. Santral sinir sistemi hasarı ve ensefalopatinin oluşum mekanizmaları tam olarak anlaşılamamıştır. Yüksek serum amonyak konsantrasyonları ve intraserebral olarak astrositlerde glutamin birikiminin ensefalopatinin esas nedeni olduğu düşünülmektedir. Bu yazıda, ciddi hiperamonemisi olmadan hızlı bir şekilde klinik bulguları kötüleşen ve artmış kreatin kinaz değerleri saptanan 10 günlük bir infant sunulmuştur

🔖

Cite This Article

BAYRAM, E., SEVER, A. H., KARAKAYA, P., TOPÇU, Y., YİŞ, U., ÇAKMAKÇI, H., DUMAN, N., ARSLAN, N., KURUL, S. H. (2014). Poor Clinical Outcome In A Good Controlled Neonatal Citrullinemia Patient. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 28 - Sayı: 1, 31–36. https://ajindex.com/articles/161325

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-1899
  2. Miyanaka K, Gotoh T, Nagasaki A, et al. Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem J 1998;30:741-751
  3. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology and therapy. Adv Pediatr 1996;43: 127-170
  4. Hudak ML, Jones D Jr, Brusilow SW. Differentiation of transient hyperammonia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 1985; 107: 712-719
  5. Beaudet AL, O’Brien WE, Bock HG, Freytag SO, Su TS. The human argininosuccinate synthetase locus and citrullinemia. Adv Hum Genet 1986;15: 161–196
  6. Bock HG, Su TS, O’Brien WE, Beaudet AL. Sequence for human argininosuccinate synthetase cDNA. Nucleic Acids Res 1983;11: 6505–6512
  7. Engel K, Hohne W, Haberle J. Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat 2009;30: 300-307
  8. Gao HZ, Kobayashi K, Tabata A, et al. Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. Hum Mutat 2003; 22: 24–34
  9. Das AM, Illsinger S, Hartmann H, et al. Prenatal benzoate treatment in urea cycle defects. Arch Dis Child Fetal Neonatal Ed 2009;94:216-217
  10. Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol 2002;7:27-35
  11. Kara B, Albayram S, Tutar O, Altun G, Koçer N, Işlak C. Diffusion-weighted magnetic resonance imaging findings of a patient with neonatal citrullinemia during acute episode. Eur J Paediatr Neurol 2009;13:280-282
  12. Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. Am J Neuroradiol 2003;24: 1184-1187
  13. Wilson CJ, Lee PJ, Leonard JV. Plasma glutamine and ammonia concentrations in ornithine carbamoyltransferase deficiency and citrullinaemia. J Inher Metab Dis 2001; 24: 691–695
  14. Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999;170:138-146
  15. Albrecht J, Sidoryk-Węgrzynowicz M, Zielinska M, Aschner M. Roles of glutamine in neurotransmission. Neuron Glia Biol 2011;21: 1-14
  16. Choi CG, Yoo HW. Localized proton MR spectroscopy in infants with urea cycle defect. Am J Neuroradiol